{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:59Z","timestamp":1790800439226,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jconrel.2015.11.018","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T02:54:35Z","timestamp":1447815275000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Inhaled drug treatment for tuberculosis: Past progress and future prospects"],"prefix":"10.1016","volume":"240","author":[{"given":"A.J.","family":"Hickey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Nardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0005","first-page":"207","article-title":"Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children","volume":"80","author":"Miller","year":"1950","journal-title":"Am. J. Dis. Child."},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2010.08.009","article-title":"Inhaled drug therapy for treatment of tuberculosis","volume":"91","author":"Misra","year":"2011","journal-title":"Tuberculosis (Edinb.)"},{"key":"10.1016\/j.jconrel.2015.11.018_bb0020","series-title":"Pharmaceutical Inhalation Aerosol Technology","article-title":"Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome","author":"Hickey","year":"2003"},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3109\/02652048.2014.932029","article-title":"The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy","volume":"31","author":"Mortensen","year":"2014","journal-title":"J. Microencapsul."},{"issue":"11","key":"10.1016\/j.jconrel.2015.11.018_bb0030","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","article-title":"Inhaled drug delivery for tuberculosis therapy","volume":"26","author":"Muttil","year":"2009","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jac\/dki027","article-title":"Antitubercular inhaled therapy: opportunities, progress and challenges","volume":"55","author":"Pandey","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2015.11.018_bb0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fcimb.2012.00118","article-title":"Pharmaceutical aerosols for the treatment and prevention of tuberculosis","volume":"2","author":"Hanif","year":"2012","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1128\/CMR.16.3.463-496.2003","article-title":"Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence","volume":"16","author":"Smith","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2015.11.018_bb0050","first-page":"1239","article-title":"Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses\u2014dual mechanisms that control bacillary multiplication. Tuberculosis: pathogenesis, protection, and control","volume":"141","author":"Dannenberg","year":"1994","journal-title":"Am. Soc. Microbiol."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.coi.2008.05.014","article-title":"Human macrophage host defense against Mycobacterium tuberculosis","volume":"20","author":"Liu","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2015.11.018_bb0060","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1136\/ard.61.suppl_2.ii54","article-title":"Protection against tuberculosis: cytokines, T cells, and macrophages","volume":"61","author":"Kaufmann","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2015.11.018_bb0065","series-title":"Controlled Pulmonary Drug Delivery","article-title":"Pulmonary drug delivery: an historical overview","author":"Sanders","year":"2011"},{"key":"10.1016\/j.jconrel.2015.11.018_bb0070","series-title":"Herbal Simples Approved for Modern Uses of Cure","author":"Fernie","year":"2008"},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/08942680152007918","article-title":"A history of nebulization","volume":"14","author":"Dessanges","year":"2001","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.jconrel.2015.11.018_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14356\/kona.1998007","article-title":"Dispersion and characterization of pharmaceutical dry powder aerosols","volume":"16","author":"Dunbar","year":"1998","journal-title":"Kona Powder Part. J."},{"issue":"9","key":"10.1016\/j.jconrel.2015.11.018_bb0085","first-page":"1209","article-title":"Dry powder inhaler formulation","volume":"50","author":"Telko","year":"2005","journal-title":"Respir. Care"},{"key":"10.1016\/j.jconrel.2015.11.018_bb0090","series-title":"Summary of common approaches to pharmaceutical aerosol administration, in Pharmaceutical Inhalation Aerosol Technology","author":"Hickey","year":"2003"},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10856-011-4511-4","article-title":"Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb)","volume":"23","author":"Lawlor","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2015.11.018_bb0100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.2042-7158.2012.01465.x","article-title":"Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state","volume":"64","author":"Gad","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2003.08.017","article-title":"Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages","volume":"269","author":"Vyas","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0110","doi-asserted-by":"crossref","DOI":"10.1208\/pt030428","article-title":"Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug","volume":"3","author":"Sethuraman","year":"2002","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/10717544.2013.851302","article-title":"Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats","volume":"21","author":"Parikh","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2015.11.018_bb0120","first-page":"2871","article-title":"Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage","volume":"8","author":"Vadakkan","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1007527204887","article-title":"Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization","volume":"17","author":"O'Hara","year":"2000","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jconrel.2009.11.020","article-title":"Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis","volume":"142","author":"Hirota","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.11.018_bb0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.colsurfb.2012.12.027","article-title":"Distribution and deposition of respirable PLGA microspheres in lung alveoli","volume":"105","author":"Hirota","year":"2013","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"9","key":"10.1016\/j.jconrel.2015.11.018_bb0140","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1023\/A:1013094112861","article-title":"Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model","volume":"18","author":"Suarez","year":"2001","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0145","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jac\/dkl369","article-title":"Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig","volume":"58","author":"Garcia-Contreras","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2008.11.027","article-title":"One-step preparation of rifampicin\/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis","volume":"135","author":"Ohashi","year":"2009","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2015.11.018_bb0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijpharm.2013.12.034","article-title":"Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis","volume":"462","author":"Maretti","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2015.11.018_bb0160","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1128\/AAC.00464-12","article-title":"Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery","volume":"56","author":"Gonzalez-Juarrero","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ja.2014.13","article-title":"Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis","volume":"67","author":"Parikh","year":"2014","journal-title":"J Antibiot."},{"issue":"7","key":"10.1016\/j.jconrel.2015.11.018_bb0170","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms12074414","article-title":"Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies","volume":"12","author":"Rojanarat","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0175","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/jps.10116","article-title":"Hydrophobic ion pairing of isoniazid using a prodrug approach","volume":"91","author":"Zhou","year":"2002","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2015.11.018_bb0180","first-page":"873","article-title":"Effects of INH (isoniazid) inhalation in patients with endobronchial tuberculosis (EBTB)","volume":"74","author":"Yokota","year":"1999","journal-title":"Kekkaku"},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0185","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijpharm.2013.04.016","article-title":"Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients","volume":"454","author":"Pham","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0190","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1021\/acs.molpharmaceut.5b00118","article-title":"Spray dried aerosol particles of salts for tuberculosis therapy","volume":"12","author":"Durham","year":"2015","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2015.11.018_bb0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/10717544.2012.721144","article-title":"Inhaled pyrazinamide proliposome for targeting alveolar macrophages","volume":"19","author":"Rojanarat","year":"2012","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1086\/317524","article-title":"Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis","volume":"32","author":"Sacks","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0205","first-page":"99","article-title":"Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis","volume":"11","author":"Giosue","year":"2000","journal-title":"Eur. Cytokine Netw."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0210","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/IAI.72.3.1275-1283.2004","article-title":"Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis","volume":"72","author":"Raju","year":"2004","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0215","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/IAI.71.4.2058-2064.2003","article-title":"Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients","volume":"71","author":"Condos","year":"2003","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0220","first-page":"636","article-title":"A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study","volume":"12","author":"Grahmann","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0225","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1378\/chest.125.6.2146","article-title":"Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis","volume":"125","author":"Condos","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3346\/jkms.2004.19.2.167","article-title":"Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis","volume":"19","author":"Koh","year":"2004","journal-title":"J. Korean Med. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0235","first-page":"594","article-title":"A case of multidrug-resistant pulmonary tuberculosis","volume":"38","author":"Tsurutani","year":"2000","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0240","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/322725","article-title":"Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis","volume":"33","author":"Parola","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0245","first-page":"769","article-title":"Treatment of ulcerative endobronchial tuberculosis and bronchial stenosis with aerosolized streptomycin and steroids","volume":"5","author":"Rikimaru","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0250","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2014.04.042","article-title":"Capreomycin inhalable powders prepared with an innovative spray-drying technique","volume":"469","author":"Schoubben","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0255","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejpb.2012.11.005","article-title":"Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization","volume":"83","author":"Schoubben","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0260","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.06145-11","article-title":"Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs","volume":"56","author":"Garcia-Contreras","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.jconrel.2015.11.018_bb0265","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01164-06","article-title":"Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model","volume":"51","author":"Garcia-Contreras","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2015.11.018_bb0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejps.2009.10.010","article-title":"Simple and scalable method for peptide inhalable powder production","volume":"39","author":"Schoubben","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0275","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1128\/AAC.01897-12","article-title":"Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice","volume":"57","author":"Verma","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0280","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1128\/AAC.05633-11","article-title":"Aerosolized gentamicin reduces the burden of tuberculosis in a murine model","volume":"56","author":"Roy","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0285","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1208\/s12249-010-9415-y","article-title":"Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles","volume":"11","author":"Wang","year":"2010","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1211\/0022357055092","article-title":"Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment","volume":"57","author":"Justo","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2015.11.018_bb0295","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijpharm.2012.10.044","article-title":"Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation","volume":"441","author":"Park","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0300","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2008.04.009","article-title":"Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis","volume":"129","author":"Hwang","year":"2008","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2012.05.045","article-title":"Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex","volume":"440","author":"Palazzo","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0310","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01389-08","article-title":"Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation","volume":"53","author":"Sung","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0315","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/AAC.01471-09","article-title":"Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs","volume":"54","author":"Garcia-Contreras","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0320","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tube.2003.08.016","article-title":"Direct lung delivery of para-aminosalicylic acid by aerosol particles","volume":"83","author":"Tsapis","year":"2003","journal-title":"Tuberculosis (Edinb.)"},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0325","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/mp4006563","article-title":"Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis","volume":"11","author":"Gupta","year":"2014","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0330","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jps.23911","article-title":"A novel inhalable form of rifapentine","volume":"103","author":"Chan","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0335","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4103\/0971-6580.155361","article-title":"Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity","volume":"21","author":"Patil-Gadhe","year":"2014","journal-title":"Toxicol. Int."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1165\/rcmb.2008-0363OC","article-title":"Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis","volume":"41","author":"Rosas-Taraco","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jbm.a.31959","article-title":"Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis","volume":"89","author":"Chimote","year":"2009","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2012.08.007","article-title":"A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics","volume":"83","author":"Chan","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijantimicag.2005.07.012","article-title":"Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis","volume":"26","author":"Ahmad","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0360","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkh411","article-title":"Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral\/aerosolized antitubercular drug carriers for treatment of tuberculosis","volume":"54","author":"Sharma","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","article-title":"Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis (Edinb.)"},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0370","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11095-013-1245-7","article-title":"A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection","volume":"31","author":"Chan","year":"2014","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2015.11.018_bb0375","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.00153-08","article-title":"Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice","volume":"52","author":"Verma","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0380","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/dkl533","article-title":"Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra","volume":"59","author":"Sharma","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2015.11.018_bb0385","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1023\/A:1012296604685","article-title":"Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis","volume":"18","author":"Sharma","year":"2001","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2015.11.018_bb0390","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tube.2010.11.003","article-title":"Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice","volume":"91","author":"Sharma","year":"2011","journal-title":"Tuberculosis (Edinb.)"},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0395","first-page":"469","article-title":"Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy","volume":"47","author":"Yadav","year":"2009","journal-title":"Indian J. Exp. Biol."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0400","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/713840401","article-title":"Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation","volume":"10","author":"Justo","year":"2003","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0405","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkg477","article-title":"Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis","volume":"52","author":"Pandey","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0410","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejps.2007.06.006","article-title":"Inhalable microparticles containing large payload of anti-tuberculosis drugs","volume":"32","author":"Muttil","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2015.11.018_bb0415","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/jphp.12094","article-title":"Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis","volume":"65","author":"Manca","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0420","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled Dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0425","doi-asserted-by":"crossref","DOI":"10.1208\/ps020434","article-title":"Effect of chloroquine on phagolysosomal fusion in cultured guinea pig alveolar macrophages: implications in drug delivery","volume":"2","author":"Bhat","year":"2000","journal-title":"AAPS PharmSci"},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0430","first-page":"687","article-title":"Certain surfactants show promise in the therapy of pulmonary tuberculosis","volume":"24","author":"Stoops","year":"2010","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.jconrel.2015.11.018_bb0435","first-page":"117","article-title":"Certain surfactants significantly enhance the activity of antibiotics in the mouse model of MTB and drug resistant MTB infection and effectively remove the bacteria from a pulmonary cavity in human ex-vivo study","volume":"44","author":"Risin","year":"2014","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.jconrel.2015.11.018_bb0440","first-page":"12","volume":"10","author":"Lovacheva","year":"2006","journal-title":"Probl. Tuberk. Bolezn. Legk."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0445","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.tube.2013.02.012","article-title":"Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis","volume":"93","author":"Verma","year":"2013","journal-title":"Tuberculosis (Edinb.)"},{"issue":"11","key":"10.1016\/j.jconrel.2015.11.018_bb0450","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/mp300269g","article-title":"Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis","volume":"9","author":"Verma","year":"2012","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2015.11.018_bb0455","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/jam.1991.4.265","article-title":"Regulatory science of inhalation aerosols","volume":"4","author":"Burke","year":"1991","journal-title":"J. Aerosol Med."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2015.11.018_bb0460","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i2-3.20","article-title":"Delivery of biotherapeutics by inhalation aerosol","volume":"12","author":"Niven","year":"1995","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0465","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/17425247.2015.995087","article-title":"Nebulizers for drug delivery to the lungs","volume":"12","author":"Martin","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.jconrel.2015.11.018_bb0470","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4155\/tde.15.18","article-title":"Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems","volume":"6","author":"Bohr","year":"2015","journal-title":"Ther. Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2015.11.018_bb0475","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/17425247.4.6.651","article-title":"Design of nanoparticle-based dry powder pulmonary vaccines","volume":"4","author":"Pulliam","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"issue":"11","key":"10.1016\/j.jconrel.2015.11.018_bb0480","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/jps.23705","article-title":"Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis","volume":"102","author":"Hickey","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0485","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11095-007-9381-6","article-title":"Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin","volume":"25","author":"Fiegel","year":"2008","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2015.11.018_bb0490","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915302418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915302418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T12:53:24Z","timestamp":1537188804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915302418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":98,"alternative-id":["S0168365915302418"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled drug treatment for tuberculosis: Past progress and future prospects","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}